This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: HIV - China Drug Forecast And Market Analysis To 2022

NEW YORK, March 20, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022

PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022


GlobalData has released its new Country report, "PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Unlike the seven major markets, the market in China mostly represents revenues generated from the sale of generics. GlobalData estimates that ViiV will launch its pipeline candidate, 572-Trii, as a novel STR in an attempt to break into this market. The NRTI class is represented mainly by generic Combivir, followed by generic lamivudine, stavudine, and generic Trizivir. The use of Gilead's Viread is expanding mainly through its combination with lamivudine.


- Overview of HIV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in China from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting China HIV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for HIV- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in China

1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 93 Disease Overview 113.1 Etiology and Pathophysiology 113.1.1 Etiology 113.1.2 Pathophysiology 143.1.3 Prognosis 143.1.4 Quality of Life 153.2 Symptoms 153.2.1 Primary or Acute Infection 153.2.2 Chronic Infection 153.2.3 Advanced Infection/AIDS 164 Disease Management 174.1 Treatment Overview 174.2 China 194.2.1 Diagnosis 194.2.2 Clinical Practice 205 Competitive Assessment 225.1 Overview 225.2 Strategic Competitor Assessment 225.3 Product Profiles – Major Brands 255.3.1 Atripla (efavirenz/emtricitabine/tenofovir) 255.3.2 Complera (emtricitabine/tenofovir/rilpivirine) 315.3.3 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) 365.3.4 Truvada (tenofovir disoproxil fumarate/emtricitabine) 415.3.5 Epzicom (abacavir/lamivudine) 455.3.6 Kaletra (lopinavir/ritonavir) 505.3.7 Reyataz (atazanavir) 545.3.8 Prezista (darunavir) 585.3.9 Norvir (ritonavir) 62 5.3.10 Isentress (raltegravir) 66 5.3.11 Entry inhibitors 706 Opportunity and Unmet Need 716.1 Overview 716.1.1 Simplified regimens and dosing frequency 726.1.2 Side effects and toxicities 726.1.3 Drug resistance 726.1.4 Prophylaxis 736.1.5 Lack of functional cure 736.1.6 Patient awareness 746.1.7 Treatment availability 756.1.8 Treatment affordability 756.2 Unmet Needs Gap Analysis 766.3 Opportunities 786.3.1 Development of treatments to counter drug resistance 786.3.2 Collaborations to develop newer STRs 786.3.3 Development of new injectable formulations 786.3.4 Development of new prophylactics 796.3.5 Development of drugs that use a novel mechanism of action 796.3.6 Public-Private Partnerships 797 Pipeline Assessment 807.1 Overview 807.2 Promising Drugs in Clinical Development 827.2.1 Cobicistat 847.2.2 Elvitegravir 917.2.3 Dolutegravir 967.2.4 572-Trii 1027.2.5 Quad 2 1088 Market Outlook 1148.1 China 1148.1.1 Forecast 1148.1.2 Key Events 1188.1.3 Drivers and Barriers 1189 Appendix 1219.1 Bibliography 1219.2 Abbreviations 1309.3 Methodology 1339.4 Forecasting Methodology 1339.4.1 HIV Prevalence 1339.4.2 Percent Drug-Treated Patients 1339.4.3 Drugs Included in Each Therapeutic Class 1349.4.4 General Pricing Assumptions 1359.4.5 Individual Drug Assumptions 1369.4.6 Generic Erosion 1419.4.7 Pricing of Pipeline agents 1419.5 Physicians and Specialists Included in this Study 1439.5.1 Survery of Prescribing Physicians 1449.6 About the Authors 1459.6.1 Authors 1459.6.2 Global Head of Healthcare 1469.7 About GlobalData 1479.8 Contact Us 1479.9 Disclaimer 147

List of Tables

Table 1: Symptoms HIV 16Table 2: Treatment Guidelines for HIV 18Table 3: Most Prescribed Drugs for HIV by Class in China Market, 2012 18Table 4: Leading Treatments for HIV, 2012 24Table 5: Product Profile – Atripla 26Table 6: Atripla SWOT Analysis, 2012 30Table 7: Product Profile – Complera 32Table 8: Complera SWOT Analysis, 2012 35Table 9: Product Profile – Stribild 37Table 10: Stribild SWOT Analysis, 2012 40Table 11: Product Profile – Truvada 42Table 12: Truvada SWOT Analysis, 2012 44Table 13: Product Profile – Epzicom 46Table 14: Epzicom SWOT Analysis, 2012 49Table 15: Product Profile – Kaletra 51Table 16: Kaletra SWOT Analysis, 2012 53Table 17: Product Profile – Reyataz 55Table 18: Reyataz SWOT Analysis, 2012 57Table 19: Product Profile – Prezista 59Table 20: Prezista SWOT Analysis, 2012 61Table 21: Product Profile – Norvir 63Table 22: Norvir SWOT Analysis, 2012 65Table 23: Product Profile – Isentress 67Table 24: Percent of Patients with HIV RNA Levels <50 Copies/mL from SMARTMRK Study 67>Table 25: Isentress SWOT Analysis, 2012 69Table 26: Summary of Minor Therapeutic Classes, 2012 70Table 27: Overall Unmet Needs – Current Level of Attainment 71Table 28: Clinical Unmet Needs – Gap Analysis, 2012 77Table 29: HIV – Promising Drugs in Clinical Development, 2012 82Table 30: Comparison of Therapeutic Classes in Development for HIV, 2012 83Table 31: Product Profile – Cobicistat 86Table 32: Cobicistat SWOT Analysis, 2012 90Table 33: Product Profile – Elvitegravir 92Table 34: Elvitegravir SWOT Analysis, 2012 95Table 35: Product Profile – Dolutegravir 98Table 36: Dolutegravir SWOT Analysis, 2012 101Table 37: Product Profile – 572-Trii 103Table 38: 572-Trii SWOT Analysis, 2012 107Table 39: Product Profile – Quad 2 110Table 40: Quad 2 SWOT Analysis, 2012 113Table 41: Sales Forecasts ($m) for HIV in China, 2012–2022 116Table 42: Key Events Impacting Sales for HIV in China, 2012–2022 118Table 43: China HIV Therapeutics Market – Drivers and Barriers, 2012–2022 118Table 44: Physicians Surveyed, By Country 144

List of Figures

Figure 1: HIV Lifecycle 12Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2012–2022 82Figure 3: Sales for HIV Therapeutics in China by Drug Class, 2012–2022 117

To order this report: Drug_and_Medication Industry: PharmaPoint: HIV - China Drug Forecast and Market Analysis to 2022

__________________________Contact Clare: US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs